Table 4 OS for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population as of July 7, 2023)

From: Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Variable

Dostarlimab + chemotherapy (N = 121)

Pembrolizumab + chemotherapy (N = 122)

Median OS follow-up time, months (IQR)

20.7 (17.3–24.0)

21.6 (18.3–24.1)

OS events observed, n

59

75

Median OS (95% CI), months

19.4 (14.5–NR)

15.9 (11.6–19.3)

Estimated probability of OS, % (95% CI)

  6 months

76 (67–83)

78 (69–84)

  12 months

63 (54–71)

58 (48–66)

Hazard ratio (95% CI)

0.75 (0.53–1.05)

  1. CI confidence interval, IQR interquartile range, ITT intention-to-treat, NR not reached, OS overall survival.
Back to article page